The financials
PTC Therapeutics, Inc. by the numbers
PTC Therapeutics, Inc. (PTCT) reported revenue of $361M in Q2 2026 (quarter ended June 30, 2026), up 102% from the same quarter a year earlier. That came with net income of $83M (23% of revenue). For the full year FY2025, revenue was $1.73B (+115% year on year) and net income $683M. Its largest product in 2026-Q1 was Sephience at $112M, 44% of the disclosed total, just ahead of Translarna at 23%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $361M | $179M | +102% |
| Operating income | $149M | −$35M | to a profit |
| Net income | $83M | −$65M | to a profit |
| Diluted EPS | $0.92 | −$0.83 | to a profit |
| Product | Revenue | Share |
|---|---|---|
| Sephience | $112M | 44% |
| Translarna | $59M | 23% |
| Royalty | $47M | 18% |
| Emflaza | $21M | 8.5% |
| Other Products | $11M | 4.3% |
| Upstaza And Kebilidi | $3.0M | 1.2% |
| Collaboration And License | $143K | 0.1% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $253.4M (+29%)
Royalty grew +29% year on yearCollaboration And License -100% year on year
Segment Latestquarter on quarteryear on year
- Sephience$112.0M$112.0MQoQ +680%year on year -+680%-
- Translarna$59.0M$59.0MQoQ +16%year on year -32%+16%-32%
- Royalty$46.8M$46.8MQoQ -34%year on year +29%-34%+29%
- Emflaza$21.5M$21.5MQoQ -39%year on year -55%-39%-55%
- Other Products$11.0M$11.0MQoQ +12%year on year +1.4%+12%+1.4%
- Upstaza And Kebilidi$3.0M$3.0MQoQ -year on year -65%--65%
- Collaboration And License$143.0K$143.0KQoQ -98%year on year -100%-98%-100%
- Manufacturing--QoQ -year on year ---
- Upstaza--QoQ -year on year ---